<DOC>
	<DOCNO>NCT02926950</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority sotagliflozin versus placebo hemoglobin A1c ( HbA1c ) reduction patient type 2 diabetes ( T2D ) inadequate glycemic control metformin . Secondary Objectives : - To compare sotagliflozin versus placebo : - Change baseline 2-hour postprandial glucose ( PPG ) follow mixed meal . - Change baseline fast plasma glucose ( FPG ) ; - Change Baseline systolic blood pressure ( SBP ) patient baseline SBP ≥130 mmHg ; - Change baseline systolic blood pressure ( SBP ) patient ; - Change baseline body weight ; - Proportion patient HbA1c &lt; 6.5 % &lt; 7.0 % . - To evaluate safety sotagliflozin versus placebo .</brief_summary>
	<brief_title>Efficacy Safety Sotagliflozin Versus Placebo Patients With Type 2 Diabetes Mellitus Background Metformin</brief_title>
	<detailed_description>Up 87 week , include Screening Period consist Screening phase 2 week 2 week single blind Run-in phase , 26 week double-blind Core Treatment Period , 53-week double-blind Extension Period , 4 week post treatment Follow-up period collect safety information .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes currently treat diet exercise metformin stable dose ≥1500 mg/day least 12 week . However , patient metformin dose &lt; 1500 mg/day time enrollment ( stable dose least 12 week enrollment ) may eligible screen documentation lack tolerance metformin dose ≥1500 mg/day provide . Signed write informed consent . Exclusion criterion : Age &lt; 18 year screen visit . Type 1 diabetes mellitus . Hemoglobin A1c &lt; 7 % &gt; 10 % via central laboratory test screening . Fasting plasma glucose ( FPG ) &gt; 15 mmol/L ( 270 mg/dL ) measure central laboratory screening ( Visit 1 ) confirm repeat test ( &gt; 15 mmol/L [ 270 mg/dL ] ) randomization . Women childbearing potential effective contraceptive method . Treated antidiabetic pharmacological regimen metformin ≥1500 mg per day ( maximum tolerate dose ) within 12 week precede Screening Visit . Previous insulin use &gt; 1 month ( time , aside treatment gestational diabetes ) . History prior gastric surgical procedure , include gastric banding , within 3 year Screening Visit . History diabetic ketoacidosis nonketotic hyperosmolar coma within 12 week prior Screening Visit . Blood pressure &gt; 180 mmHg ( systolic ) &gt; 95 mmHg ( diastolic ) . History hypertensive emergency . Patients severe anemia , severe cardiovascular ( include congestive heart failure New York Heart Association ( NYHA ) III/IV ) , respiratory , hepatic , neurological , psychiatric , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult . Aspartate aminotransferase and/or alanine aminotransferase : &gt; 3 time upper limit normal laboratory range . Total bilirubin : &gt; 1.5 time upper limit normal laboratory range ( except case Gilbert 's syndrome ) . Use systemic glucocorticoid ( exclude topical ophthalmic application inhale form ) 10 consecutive day within 90 day prior Screening Visit . Patient take investigational drug prohibit therapy study within 12 week 5 halflives screen randomization , whichever longer . Pregnant ( demonstrate serum pregnancy test Screening ) breastfeed woman . Patient unwilling perform selfmonitoring blood glucose ( SMBG ) complete patient diary require per protocol . Contraindication metformin per local labeling . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>